Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BFP-TA is the total alkaloid extract from Bulbus Fritillariae pallidiflorae, a traditional Chinese medicinal plant. BFP-TA has demonstrated therapeutic effects in preclinical models of chronic obstructive pulmonary disease (COPD), where it reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), mitigates oxidative stress, and modulates matrix metalloproteinases (MMP-9, MMP-12) and their inhibitor TIMP-1. Its mechanism appears to involve inhibition of the MAPK pathway, modulation of the SIRT1/Nrf2/Keap1 axis, and regulation of PPAR and PI3K-Akt signaling pathways. The active constituents are alkaloids but individual chemical identification remains to be clarified. BFP-TA is under investigation for lung disease, primarily COPD, in preclinical models[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BFP-TA.